| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/09/2011 | EP2292598A2 An improved process for the preparation of xanthophyll crystals |
| 03/09/2011 | EP2292596A2 CETP activity inhibitor |
| 03/09/2011 | EP2292595A1 Potassium channel modulators |
| 03/09/2011 | EP2292593A2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| 03/09/2011 | EP2292592A1 Sulfonamide compound and application thereof |
| 03/09/2011 | EP2292590A2 Prodrugs of 9-aminomethyl tetracycline compounds |
| 03/09/2011 | EP2292589A1 Novel multifunctional peptidase inhibitors, especially for medical use |
| 03/09/2011 | EP2292588A1 Ceramide dimers and their use as medicine or cosmetic preparation |
| 03/09/2011 | EP2292587A1 Pharmaceutical composition for inhibiting the transcription factor inducible by hypoxia, modulators of pathological processes of angiogenesis, oncogenesis, inflammation, apoptosis, and cellular therapy |
| 03/09/2011 | EP2292584A1 Levalbuterol L-hemitartrate salt and aerosol formulation thereof |
| 03/09/2011 | EP2292577A1 (+)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof |
| 03/09/2011 | EP2292576A2 Retinoids useful in the treatment of cancer and for reducing serum triglycerides |
| 03/09/2011 | EP2292280A1 Medical devices containing rapamycin analogs |
| 03/09/2011 | EP2292270A1 Drug carrier |
| 03/09/2011 | EP2292268A1 Pharmaceutical composition for use in treatment of diabetes |
| 03/09/2011 | EP2292267A2 Combinations comprising antimuscarinic agents and beta-adrenergic agonists |
| 03/09/2011 | EP2292265A1 Set of antiangiogenic molecules and use thereof |
| 03/09/2011 | EP2292244A2 Salt Solution for Colon Cleansing |
| 03/09/2011 | EP2292243A1 Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease |
| 03/09/2011 | EP2292242A1 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof |
| 03/09/2011 | EP2292241A1 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof |
| 03/09/2011 | EP2292240A1 Use of rapamycin for treatment or prevention of Alzheimer's Disease |
| 03/09/2011 | EP2292239A2 Remedies for diseases to be applied to eye |
| 03/09/2011 | EP2292238A1 Use of Steroids or Glucocorticoids for treatment or prevention of Alzheimer's Disease |
| 03/09/2011 | EP2292237A1 Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| 03/09/2011 | EP2292236A1 Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| 03/09/2011 | EP2292235A2 Methotrexate solutions |
| 03/09/2011 | EP2292234A1 Compositions comprising quinazoline derivatives, preparation methods and uses thereof |
| 03/09/2011 | EP2292233A2 Pharmaceutical uses of N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine |
| 03/09/2011 | EP2292232A1 Beta-amino tetrahydroimidazo(1,2-A)pyrazines and tetrahydrotriazolo(4,3-A)pyrazines for use in the treatment of diabetes type II |
| 03/09/2011 | EP2292231A1 Therapeutic agent for spinal canal stenosis |
| 03/09/2011 | EP2292230A1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 03/09/2011 | EP2292229A1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 03/09/2011 | EP2292228A1 Pyrazole derivatives as 11-beta-HSD1 inhibitors |
| 03/09/2011 | EP2292227A2 Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity |
| 03/09/2011 | EP2292226A2 The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin |
| 03/09/2011 | EP2292225A1 Dosage form comprising taxol in crystalline form |
| 03/09/2011 | EP2292224A1 Precursor compounds of sweet receptor antagonists for preventing or treating diabetes |
| 03/09/2011 | EP2292223A1 Polyunsaturated fatty acid supplements |
| 03/09/2011 | EP2292222A1 Polymorphic Forms of a GABAA Agonist |
| 03/09/2011 | EP2292221A2 Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| 03/09/2011 | EP2292220A2 Composition and methods for increasing insulin sensitivity |
| 03/09/2011 | EP2292219A1 Transdermal therapeutic system for the administration of rivastigmine |
| 03/09/2011 | EP2292218A2 Nimesulide and muscle relaxant combinations thereof |
| 03/09/2011 | EP2292217A2 Modified release lamotrigine tablets |
| 03/09/2011 | EP2292216A2 Stable pharmaceutical composition containing factor VIII |
| 03/09/2011 | EP2292214A1 Highly absorbable drug composition and method of producing the same |
| 03/09/2011 | EP2292213A1 Compositions comprising a polymorphic form of armodafinil |
| 03/09/2011 | EP2292211A2 Mucoadhesive pharmaceutical formulations |
| 03/09/2011 | EP2292210A1 Preparation for the prevention and/or treatment of dementia syndromes |
| 03/09/2011 | EP2292209A2 Stable pharmaceutical composition comprising a pyramidine-sulfamide |
| 03/09/2011 | EP2292208A1 External preparation for skin |
| 03/09/2011 | EP2292088A1 Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| 03/09/2011 | EP2291383A1 New classes of gabaa/bzr ligands |
| 03/09/2011 | EP2291381A1 Novel 2-substituted quinoline derivatives, and method for preparing same |
| 03/09/2011 | EP2291380A1 Nalmefene prodrugs |
| 03/09/2011 | EP2291379A1 Substituted quinazolines |
| 03/09/2011 | EP2291377A1 Imidazopyrimidinones and uses thereof |
| 03/09/2011 | EP2291376A2 Naphthyridininones as aurora kinase inhibitors |
| 03/09/2011 | EP2291375A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives |
| 03/09/2011 | EP2291373A1 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 03/09/2011 | EP2291372A2 Intestinal alkaline phosphatase modulators and uses thereof |
| 03/09/2011 | EP2291371A1 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 03/09/2011 | EP2291370A1 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 03/09/2011 | EP2291369A1 Phenyl and benzodioxinyl substituted indazoles derivatives |
| 03/09/2011 | EP2291368A1 Substituted gamma lactams as therapeutic agents |
| 03/09/2011 | EP2291367A1 Substituted gamma lactams as therapeutic agents |
| 03/09/2011 | EP2291365A1 5-substituted isoindoline compounds |
| 03/09/2011 | EP2291360A2 Solid state forms of deferasirox salts and process for the preparation thereof |
| 03/09/2011 | EP2291359A1 Phenyl or pyridinyl substituted indazoles derivatives |
| 03/09/2011 | EP2291358A1 Glucagon receptor antagonists, compositions, and methods for their use |
| 03/09/2011 | EP2291355A2 Novel tetrahydroquinolines as aromatase inhibitors |
| 03/09/2011 | EP2291353A1 Therapeutic prostaglandin compounds used as ocular hypotensive agents |
| 03/09/2011 | EP2291352A2 N-acylthiourea and n-acylurea inhibitors of the hedgehog protein signalling pathway |
| 03/09/2011 | EP2291351A1 Alpha-mercapto-amides |
| 03/09/2011 | EP2291350A2 Compositions and methods for preparing and using same |
| 03/09/2011 | EP2291346A2 Therapeutic substituted cyclopentanes |
| 03/09/2011 | EP2291345A1 Co-crystals of duloxetine and cox-inhibitors for the treatment of pain |
| 03/09/2011 | EP2291199A2 Capsulating system binding to nucleolin |
| 03/09/2011 | EP2291197A1 Use of histamine h4 antagonist for the treatment of post-operative adhesions |
| 03/09/2011 | EP2291193A1 Preparation of intermediates useful in the syntheis of 2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosylcytosine |
| 03/09/2011 | EP2291192A2 Anticancer methods using extracts of anemerrhena asphodeloides bungle |
| 03/09/2011 | EP2291191A1 Methods for preventing and treating neurodegenerative diseases |
| 03/09/2011 | EP2291190A2 Vaccine composition containing synthetic adjuvant |
| 03/09/2011 | EP2291189A1 Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
| 03/09/2011 | EP2291188A2 Compositions and methods to protect cells by blocking entry of pathogen proteins |
| 03/09/2011 | EP2291187A2 Ido inhibitors |
| 03/09/2011 | EP2291186A2 Materials and methods for suppressing and/or treating neurofibroma and related tumors |
| 03/09/2011 | EP2291185A1 Octenidine composition |
| 03/09/2011 | EP2291184A2 Antiviral drugs for treatment of arenavirus infection |
| 03/09/2011 | EP2291183A2 Use of dronedarone for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level due to dronedarone administration |
| 03/09/2011 | EP2291182A1 Salicylate conjugates useful for treating metabolic disorders |
| 03/09/2011 | EP2291181A2 Psycho-pharmaceuticals |
| 03/09/2011 | EP2291180A1 Anhydrous depigmenting compositions comprising, within the fatty phase, a solubilized phenolic derivative and a retinoid |
| 03/09/2011 | EP2291179A2 Novel anhydrous depigmenting compositions comprising a solubilized phenolic derivative |
| 03/09/2011 | EP2291178A2 Controlled release formulations of pramipexole |
| 03/09/2011 | EP2291177A2 Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale |
| 03/09/2011 | EP2291176A1 Steroid nebuliser formulation |
| 03/09/2011 | EP2291084A1 Carbonate prodrugs and methods of using the same |
| 03/09/2011 | EP2291081A1 Povidone iodine, a novel alternative preservative for ophthalmic compositions |